|
|
|
|
| LEADER |
00000pam a22000004a 4500 |
| 001 |
5774901 |
| 003 |
ICU |
| 005 |
20090309163000.0 |
| 008 |
050414s2006 mdua b 001 0 eng |
| 010 |
|
|
|a 2005010684
|
| 020 |
|
|
|a 0781744318
|
| 035 |
|
|
|a (OCoLC)59148565
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d UtOrBLW
|d OrLoB-B
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM301.5
|b .A66 2006
|
| 060 |
0 |
0 |
|a QV 38
|b A6527 2006
|
| 082 |
0 |
0 |
|a 615/.7
|2 22
|
| 245 |
0 |
0 |
|a Applied pharmacokinetics & pharmacodynamics :
|b principles of therapeutic drug monitoring /
|c editors, Michael E. Burton ... [et al.].
|
| 246 |
3 |
|
|a Applied pharmacokinetics and pharmacodynamics
|
| 250 |
|
|
|a 4th ed.
|
| 260 |
|
|
|a Baltimore :
|b Lippincott Williams & Wilkins,
|c c2006.
|
| 300 |
|
|
|a xvii, 867 p. :
|b ill. ;
|c 29 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 500 |
|
|
|a Rev. ed. of: Applied pharmacokinetics / edited by William E. Evans, Jerome J. Schentag, William J. Jusko. 3rd ed. c1992.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g 1.
|t General principles of clinical pharmacokinetics /
|r William E. Evans --
|g 2.
|t Guidelines for collection and analysis of pharmacokinetic data /
|r William J. Jusko --
|g 3.
|t Critical evaluation of methods for therapeutic drug monitoring /
|r Victor W. Armstrong and Michael Oellerich --
|g 4.
|t Analysis of pharmacokinetic data for individualizing drug dosage regimens /
|r John H. Rodman, David Z. D'Argenio and Carl C. Peck --
|g 5.
|t Pharmacodynamics /
|r Richard L. Lalonde --
|g 6.
|t Influence of protein binding and use of unbound (free) drug concentrations /
|r Janis J. MacKichan --
|g 7.
|t Drug metabolism, transport, and the influence of hepatic disease /
|r Angela D. M. Kashuba, Joohyun J. Park, Adam M. Persky and Kim L. R. Brouwer --
|g 8.
|t Application of pharmacogenetic principles to clinical pharmacology /
|r Mark W. Linder, William E. Evans and Howard L. McLeod --
|g 9.
|t Influence of renal function and dialysis on drug disposition /
|r Gary R. Matzke and Thomas J. Comstock --
|g 10.
|t Special pharmacokinetic and pharmacodynamic considerations in children /
|r Holly D. Maples, Laura P. James and Cindy D. Stowe --
|g 11.
|t Special pharmacokinetic considerations in the obese /
|r Robert A. Blouin and Mary H. H. Ensom --
|g 12.
|t Dietary influences on drug disposition /
|r Mary H. H. Ensom and Robert A. Blouin --
|g 13.
|t Asthma management /
|r Glenn J. Whelan and Stanley J. Szefler --
|g 14.
|t Aminoglycosides /
|r Jerome J. Schentag, Alison K. Meagher and Roger W. Jelliffe --
|g 15.
|t Vancomycin /
|r Pamela A. Moise-Broder --
|g 16.
|t Microbiologic, clinical, and economic outcomes of dual individualized dosing of antimicrobial agents /
|r Joseph A. Paladino and Jerome J. Schentag --
|g 17.
|t Antivirals for HIV /
|r Craig R. Rayner, Michael J. Dooley and Roger L. Nation --
|g 18.
|t Digoxin /
|r Jerome J. Schentag, Anthony J. Bang and Jennifer L. Kozinski-Tober --
|g 19.
|t Clinical pharmacokinetics of oral antiarrhythmic drugs /
|r Jerry L. Bauman, Harumi Takahashi and James H. Fischer --
|g 20.
|t Phenytoin /
|r Michael E. Winter and Thomas N. Tozer --
|g 21.
|t Antiepileptic drugs /
|r William R. Garnett, Gail D. Anderson and Rebeccah J. Collins --
|g 22.
|t Cyclosporine /
|r Atholl Johnston and David W. Holt --
|g 23.
|t Tacrolimus /
|r Uwe Christians, Taveesak Pokaiyavanichkul and Laurence Chan --
|g 24.
|t Mycophenolic acid /
|r Arthur Nawrocki, Magdalena Korecka, Sandra Solari, Juseop Kang and Leslie M. Shaw --
|g 25.
|t Sirolimus /
|r Barry D. Kahan and Kimberly L. Napoli --
|g 26.
|t Anticancer agents /
|r William P. Petros and William E. Evans --
|g 27.
|t Heparin - UFH and LMWH /
|r Keith A. Rodvold, Sharon M. Erdman, Kelly A. Sprandel, Robert J. Cipolle and Eleanor S. Pollak --
|g 28.
|t Warfarin /
|r Stuart T. Haines, Thomas Dowling and R. Donald Harvey III --
|g 29.
|t Nonsteroidal anti-inflammatory drugs and coxibs /
|r Tilo Grosser --
|g 30.
|t Cyclic antidepressants /
|r C. Lindsay DeVane --
|g 31.
|t Lithium /
|r Tawny L. Bettinger and M. Lynn Crismon --
|g 32.
|t Antipsychotics /
|r James M. Perel and Michael W. Jann --
|g App.
|t A critical assessment of the outcomes of therapeutic drug monitoring /
|r Mary H. H. Ensom and Michael E. Burton.
|
| 650 |
|
0 |
|a Pharmacokinetics.
|0 http://id.loc.gov/authorities/subjects/sh00006940
|
| 650 |
|
0 |
|a Drug monitoring.
|0 http://id.loc.gov/authorities/subjects/sh91006436
|
| 650 |
1 |
2 |
|a Pharmacokinetics.
|
| 650 |
2 |
2 |
|a Drug Monitoring.
|
| 650 |
2 |
2 |
|a Pharmacology.
|
| 650 |
|
7 |
|a Drug monitoring.
|2 fast
|0 http://id.worldcat.org/fast/fst00898688
|
| 650 |
|
7 |
|a Pharmacokinetics.
|2 fast
|0 http://id.worldcat.org/fast/fst01060250
|
| 700 |
1 |
|
|a Burton, Michael E.
|0 http://id.loc.gov/authorities/names/nb99140502
|1 http://viaf.org/viaf/164219781
|
| 730 |
0 |
|
|a Applied pharmacokinetics.
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i d5df06a2-dd7b-51db-a0c4-0dc36baa38f0
|s 8f1282e6-c888-5aa5-8a6a-1f07b4a14631
|
| 928 |
|
|
|t Library of Congress classification
|a RM301.5 .A66 2006
|l JCL
|c JCL-Sci
|i 4986233
|
| 928 |
|
|
|t Library of Congress classification
|a RM301.5 .A66 2006
|l JCL
|c JCL-Sci
|i 5022685
|
| 927 |
|
|
|t Library of Congress classification
|a RM301.5 .A66 2006
|l JCL
|c JCL-Sci
|e CRERAR
|b 70969863
|i 7927762
|
| 927 |
|
|
|t Library of Congress classification
|a RM301.5 .A66 2006
|l JCL
|c JCL-Sci
|e BILL
|e CRERAR
|b 088619362
|i 7927763
|
